fashion -WSS

fashion

author：explore 2025-09-27 12:56:53 - browse：77

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： How to save health care price transparency rules

hotspot

WSS

Gene therapy for Afghan refugees’ infant will be fully covered

Male and female sex labels in research insufficient, scientists say

Unique patient identifier: Experts argue the benefits, pitfalls

Problems with a popular proposal to regulate AI in health care

The CDC's new social media misinformation war

Surgery pushed Ben Carson to fame

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Bright Health sells Medicare Advantage business to Molina

Male and female sex labels in research insufficient, scientists say

Hepatitis C has a cure — but many Americans still lack access to it

Why scientists need input from humanists on sensitive research

23andMe had bad news about my health. I wish a person had delivered it

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Medical records are filled with copy

John Green on his newest strategy for fighting tuberculosis

focus

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

First U.S. drug developed to treat liver disease MASH is approved

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Readout Newsletter: Bristol, Sangamo, Gilead, and more

How many hemophilia patients actually want gene therapy?

focus

leisure time

hotspot

leisure time